- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT06493084
Оцените LAE102 у здоровых субъектов и субъектов с избыточным ожирением.
Рандомизированное двойное слепое плацебо-контролируемое исследование фазы I с однократным и многократным повышением дозы для оценки безопасности, переносимости и фармакокинетики LAE102 у здоровых субъектов и субъектов с избыточным весом/ожирением
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of LAE102 injection in healthy and overweight/obese participants, and also evaluate the preliminary pharmacodynamic effect of multiple dose injections in overweight/obese participants.
Обзор исследования
Статус
Вмешательство/лечение
Подробное описание
Part A is a randomized, double-blinded, placebo-controlled, single ascending dose by Intravenous (IV) administration in 40 Healthy participants;
Part B is a randomized, double-blinded, placebo-controlled, single ascending dose by subcutaneous (SC) administration in 24 Healthy participants;
Part C is a randomized, double-blind, placebo-controlled, multiple dose ascending and expanding by subcutaneous (SC) administration in 60 overweight/obese participants.
Тип исследования
Регистрация (Оцененный)
Фаза
- Фаза 1
Контакты и местонахождение
Места учебы
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Китай, 201203
- Fudan Zhongshan Hospital
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Male or female and aged 18 to 65 years (inclusive) at the screening visit
- Male Body weight ≥ 50 kg, female Body weight ≥ 45 kg. For Part A&B, 18.5 ≤ BMI ≤ 28 kg/m². For part C, 26.0 ≤ BMI ≤ 40.0 kg/m²
- Negative for human immunodeficiency virus antibody (HIV-Ab).
- Female subjects with no childbearing potential or with childbearing potential which serum human chorionic gonadotropin (hCG) test must <5mIU/mL .
- Male subjects are not allowed to donate sperm during this trial.
- Voluntarily participate in the study and provide a signed and dated informed consent form.
- Willing to comply with the scheduled visits, study treatment, laboratory tests, and other study-related procedures and requirements as stipulated in the study protocol.
Exclusion Criteria:
- With clinically significant abnormalities in vital signs, physical examination, ECG or laboratory test results specified in the protocol.
- Allergy to the investigational drug or its excipients, or a history of severe allergy (including any food or drug allergies).
- Self-reported weight change is more than 5% in the previous 3 months prior to screening.
- Diagnosed with secondary overweight or obesity.
- Any clinically significant medical conditions and any diseases affecting the safety of the subject or the determination of study results.
- History of major diseases or physical conditions in the central nervous system, respiratory system, cardiovascular system, digestive system, blood system, endocrine system, musculoskeletal diseases, mental illness, urinary system, or tumors, or any existing acute diseases, or other diseases or physical conditions that may affect the study or pose an unacceptable risk to the subjects.
- Positive for hepatitis B surface antigen (HBsAg), or hepatitis C antibody (HCV-Ab), or syphilis spirochete antibody (TP-Ab).
- Known or suspected history of substance abuse or positive drug screening test.
- Alcohol abuse within 1 year before screening or positive alcohol breath test at baseline.
- Smoking more than 5 cigarettes per day within 3 months before screening, or unable to comply with the prohibition of smoking during the study period.
- Received any vaccine within 30 days prior to screening, or planned to receive any vaccine during the study period.
- Inability to ensure no use of any drugs, including prescription and non-prescription drugs (excluding paracetamol, ibuprofen, and topically applied eye/nasal drops and ointments with no systemic exposure risk), vitamins, supplements and herbal medicines, from 14 days before the initial administration (if the half-life of the drug used exceeds 14 days, then 5 half-lives shall apply) until the last visit period.
- Participated in any clinical trial and received an investigational medicine or medical device within 3 months prior to dosing of the investigational product.
- Underwent major surgery within 30 days before the initial administration or planned to undergo major surgery during the study period.
- Donated blood or experienced blood loss ≥400 mL within 3 months before screening or received a blood transfusion.
- Have special dietary requirements and cannot comply with a standardized diet.
- History of fainting or syncope.
- Dieting or receiving weight loss treatment within 30 days before the initial administration or experiencing major changes in lifestyle.
- Use of GLP-1 receptor agonists, or weight loss medications or systemic corticosteroids (oral or intravenous for more than 7 days), or psychiatric medications within 3 months prior to the initial administration. Applicable to part C.
- Regular engaged in muscle strength related exercise, applicable to part C.
- Other situation that the investigator considers not appropriate.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Последовательное назначение
- Маскировка: Четырехместный
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Part A LAE102 IV
Single dose LAE102 by IV administration |
A single dose of LAE102 administered intravenously
Другие имена:
|
|
Плацебо Компаратор: Part A placebo IV
Single dose placebo by IV administration |
A single dose of placebo administered intravenously
Другие имена:
|
|
Экспериментальный: Part B LAE102 SC
Single dose LAE102 by SC administration |
Single dose of LAE102 administered subcutaneously
Другие имена:
|
|
Плацебо Компаратор: Part B placebo SC
Single dose placebo by SC administration |
single dose of placebo administered subcutaneously
Другие имена:
|
|
Экспериментальный: Part C LAE102 SC
Multiple dose LAE102 by SC administration |
Multiple dose of LAE102 administered subcutaneously
Другие имена:
|
|
Плацебо Компаратор: Part C placebo SC
Multiple dose placebo by SC administration |
Multiple dose of placebo administered subcutaneously
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Number & severity of participants with treatment-related adverse events as assessed by CTCAE V5.0
Временное ограничение: From Day 1 to Day 29 for single dose part. From Day 1 to Day 196 for multiple dose part
|
Findings on physical examination, ECG, vital signs, and reports of the laboratory results based on the CTCAE v5.0 |
From Day 1 to Day 29 for single dose part. From Day 1 to Day 196 for multiple dose part
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
characterize the peak of serum concentration (Cmax) of LAE102 injection in healthy subjects
Временное ограничение: From pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
|
For both intravenously guttae & subcutaneous injection, to evaluate the maximum observed serum concentration(Cmax) |
From pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
|
|
characterize the area under the serum concentration versus time curve (AUC) of LAE102 injection in healthy subjects
Временное ограничение: From pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
|
For both intravenously guttae & subcutaneous injection, to evaluate the area under the serum concentration versus time curve (AUC) |
From pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
|
|
evaluate the expression levels of Activin A in blood samples
Временное ограничение: From pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
|
The validated methodology was employed to assay serum levels of Activin A in biological samples. |
From pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
|
|
Incidence of positive Anti-drug antibody(ADA) after administration
Временное ограничение: pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
|
Test ADA status in biological sample via validated methodology |
pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
|
Другие показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Preliminary pharmacodynamic of total body weight for multiple dose part
Временное ограничение: From pre-dose to Day 168.
|
Changes and percentage changes in total body weight (kg) after administration |
From pre-dose to Day 168.
|
|
Preliminary pharmacodynamic of lean mass for multiple dose part
Временное ограничение: From pre-dose to Day 168.
|
Changes and percentage changes in lean mass after administration |
From pre-dose to Day 168.
|
|
Preliminary pharmacodynamic of fat mass for multiple dose part
Временное ограничение: From pre-dose to Day 168.
|
Changes and percentage changes in fat mass after administration |
From pre-dose to Day 168.
|
|
Preliminary pharmacodynamic of thigh muscle volume for multiple dose part
Временное ограничение: From pre-dose to Day 168
|
Changes and percentage changes in thigh muscle volume after administration |
From pre-dose to Day 168
|
|
Preliminary pharmacodynamic of bone mineral density(BMD) for multiple dose part
Временное ограничение: From pre-dose to Day 168
|
Changes and percentage changes in BMD after administration |
From pre-dose to Day 168
|
|
BMI/waist circumference change and percentage.
Временное ограничение: From pre-dose to Day 29 forsingle dose. From pre-dose to Day 196 for multiple dose.
|
Assess the Body Mass Index (BMI)/waist circumference change and percentage. |
From pre-dose to Day 29 forsingle dose. From pre-dose to Day 196 for multiple dose.
|
Соавторы и исследователи
Спонсор
Следователи
- Главный следователь: Xuening Li, Professor, Zhongshan hospital affiliated to Fundan University
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- LAE102CN1001
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
продукт, произведенный в США и экспортированный из США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .